The Latest Cardiac and Vascular News
The FDA has provided valuable feedback to reinforce the proposed clinical development plan of glenzocimab in acute ischemic stroke (AIS) A new Type C consultation with the FDA has been granted on the pharmaceutical development plan In Europe additional scientific advice requests under the PRIME program have been validated by […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of March 31, 2023 (pursuant to Article L. 233-8 II of […]
Key milestones achieved in the two Phase 2/3 studies in stroke with glenzocimab: ACTISAVE study: more than 240 patients enrolled to date GREEN study: enrollment of the first patients Exchanges between the University of Birmingham and the UK regulatory authorities for the LIBERATE study in the treatment of myocardial infarction […]
PARIS–(BUSINESS WIRE)–Regulatory News: Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Australia or Japan. This press release does not constitute an offering document and is for information purposes only. ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT – the “Company“), a clinical-stage biotechnology company […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of January 31, 2023 (pursuant to Article L. 233-8 II of the […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, is announcing today the appointment of Patricia Zilliox as an independent director to replace Corinne Le Goff, whose plurality of […]
Enrollment of the 200th patient in the ACTISAVE study Initiation of patient enrollment in the GREEN Phase 2/3 study in stroke Update on the clinical evaluation of glenzocimab in stroke and myocardial infarction January 09, 2023 12:00 PM Eastern Standard Time PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), […]
PARIS–(BUSINESS WIRE)–Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, is discussing with FDA to set up a Type C meeting for early 2023 with the same objective as for the recent meeting with the […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of November 30, 2022 (pursuant to Article L. 233-8 II of the […]
Approval of ACTISAVE design by the EMA to support a potential future marketing authorization application (MAA) for glenzocimab in Stroke Validation du choix d’un double critère d’évaluation principal : – Échelle de Rankin modifiée (mRS)1 – Échec (versus succès) défini par un handicap grave ou le décès, soit un score mRS 4-6 […]
